These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37641627)

  • 41. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-Alcoholic Components in Huangjiu as Potential Factors Regulating the Intestinal Barrier and Gut Microbiota in Mouse Model of Alcoholic Liver Injury.
    Yang Y; Zhou Z; Liu Y; Xu X; Xu Y; Zhou W; Chen S; Mao J
    Foods; 2022 May; 11(11):. PubMed ID: 35681289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intake of Bifidobacterium lactis Probio-M8 fermented milk protects against alcoholic liver disease.
    He Q; Yang C; Kang X; Chen Y; Zhang T; Zhang H; Kwok LY
    J Dairy Sci; 2022 Apr; 105(4):2908-2921. PubMed ID: 35086715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pomegranate prevents binge alcohol-induced gut leakiness and hepatic inflammation by suppressing oxidative and nitrative stress.
    Cho YE; Song BJ
    Redox Biol; 2018 Sep; 18():266-278. PubMed ID: 30071471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gut-liver axis in alcoholic liver disease.
    Szabo G
    Gastroenterology; 2015 Jan; 148(1):30-6. PubMed ID: 25447847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microbiota, a key player in alcoholic liver disease.
    Cassard AM; Ciocan D
    Clin Mol Hepatol; 2018 Jun; 24(2):100-107. PubMed ID: 29268595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Probiotics and liver disease.
    Sharma V; Garg S; Aggarwal S
    Perm J; 2013; 17(4):62-7. PubMed ID: 24361022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gut microbiome and liver diseases.
    Tilg H; Cani PD; Mayer EA
    Gut; 2016 Dec; 65(12):2035-2044. PubMed ID: 27802157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatoprotective effect of curcumin against bisphenol A-induced hepatic steatosis via modulating gut microbiota dysbiosis and related gut-liver axis activation in CD-1 mice.
    Hong T; Jiang X; Zou J; Yang J; Zhang H; Mai H; Ling W; Feng D
    J Nutr Biochem; 2022 Nov; 109():109103. PubMed ID: 35780999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gut dysbiosis correction contributes to the hepatoprotective effects of
    Yan X; Wang Y; Ren XY; Liu XY; Ma JM; Song RL; Wang XH; Dong Y; Yu AX; Fan QQ; Wei J; She GM
    Food Funct; 2021 Oct; 12(20):10281-10290. PubMed ID: 34549762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut Microbiome and Alcohol-associated Liver Disease.
    Philips CA; Schnabl B; Bajaj JS
    J Clin Exp Hepatol; 2022; 12(5):1349-1359. PubMed ID: 36157139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synbiotics, prebiotics and probiotics for solid organ transplant recipients.
    Cooper TE; Scholes-Robertson N; Craig JC; Hawley CM; Howell M; Johnson DW; Teixeira-Pinto A; Jaure A; Wong G
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014804. PubMed ID: 36126902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microbiota, Liver Diseases, and Alcohol.
    Cassard AM; Gérard P; Perlemuter G
    Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research.
    Neuman MG; Seitz HK; French SW; Malnick S; Tsukamoto H; Cohen LB; Hoffman P; Tabakoff B; Fasullo M; Nagy LE; Tuma PL; Schnabl B; Mueller S; Groebner JL; Barbara FA; Yue J; Nikko A; Alejandro M; Brittany T; Edward V; Harrall K; Saba L; Mihai O
    Biomedicines; 2020 Mar; 8(3):. PubMed ID: 32197424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.